Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.

ABSTRACT:

Objective

To determine whether ciclosporin is superior to prednisolone for the treatment of pyoderma gangrenosum, a painful, ulcerating skin disease with a poor evidence base for management.

Design

Multicentre, parallel group, observer blind, randomised controlled trial.

Setting

39 UK hospitals, recruiting from June 2009 to November 2012.

Participants

121 patients (73 women, mean age 54 years) with clinician diagnosed pyoderma gangrenosum. Clinical diagnosis was revised in nine participants after randomisation, leaving 112 participants in the analysis set (59 ciclosporin; 53 prednisolone).

Intervention

Oral prednisolone 0.75 mg/kg/day compared with ciclosporin 4 mg/kg/day, to a maximum dose of 75 and 400 mg/day, respectively.

Main outcome measures

SUBMITTER: Ormerod AD 

PROVIDER: S-EPMC4469977 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature